Iterum Therapeutics (ITRM) AI Stock Analysis

• Market Cap: $17.22M
• Dividend Yield: N/A
• Average Volume (3M): 813.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: 62.61%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 52,835,200
• 10 Day Avg. Volume: 1,119,323
• 30 Day Avg. Volume: 813,222
• PEG Ratio: 0.02
• Price to Book (P/B): -8.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.30
• Enterprise Value/Market Cap: 3.44
• Enterprise Value/Revenue: 151.97
• Enterprise Value/Gross Profit: -88.72
• Enterprise Value/Ebitda: -2.57
• 1Y Price Target: $5.50
• Price Target Upside: 1517.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.32 ▼(-7.35% Downside)

The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.

Positive Factors

Differentiated antibiotic addressing resistance

Bringing a novel oral antibiotic to a uUTI market with rising resistance offers durable clinical differentiation. Limited recent competition and a clear unmet need can sustain prescriber interest, underpinning long-term product adoption and a structural addressable market if reimbursement expands.

Early prescriber adoption and commercial traction

Meaningful early prescriptions and a growing prescriber base indicate clinician acceptance and real-world utility. This early uptake, combined with targeted field efforts and distributor stocking, supports a scalable commercial roll-out and durable revenue building as payer coverage improves.

Expanding market access and patent estate

Securing PBM rebate agreements and advancing formulary inclusion materially reduces access barriers, creating durable demand potential across Medicare and commercial lives. Coupled with granted patents extending protection into 2039–2041, this supports sustained exclusivity and revenue capture over the medium term.

Negative Factors

Very limited revenue and persistent losses

Minimal product revenue and deep, ongoing losses create a long runway requirement for commercial break-even. Structural profitability depends on successful scale, which is uncertain; continued negative margins increase financing needs and heighten the risk that commercialization won't achieve self-sustaining cash generation.

Negative equity and elevated leverage

Negative equity and debt exceeding assets constrain financial flexibility and creditor confidence. This capital structure raises refinancing and covenant risk, increasing the likelihood of dilution or onerous financing terms that could impair long-term investment in commercialization and R&D.

Capital runway and Nasdaq listing risk

A narrow cash runway into 2026 and explicit plans to raise capital create structural execution risk. Concurrent Nasdaq non-compliance pressures access to public markets and could limit financing options, forcing dilutive raises or operational cuts that would hinder long-term commercialization and growth plans.

Iterum Therapeutics Business Overview & Revenue Model

Company Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

How the Company Makes Money

Iterum Therapeutics makes money through the development and potential commercialization of its primary product candidate, sulopenem. The company's revenue model is expected to include income from the sale of sulopenem upon receiving regulatory approval, which would allow the company to market the drug to healthcare providers and institutions. Additionally, Iterum may pursue licensing agreements, strategic partnerships, and collaborations with other pharmaceutical companies to enhance distribution and commercialization efforts. These partnerships could provide upfront payments, milestone payments, and royalties based on sales, contributing significantly to the company's earnings. As a clinical-stage company, Iterum may also rely on funding from investors, grants, and other financial instruments to support its research and development activities until its products reach the market.

Iterum Therapeutics Financial Statement Overview

Summary

Iterum Therapeutics is struggling financially with consistent net losses, negative cash flows, and a weak balance sheet. The lack of revenue and profitability, coupled with financial instability, underlines significant challenges the company must address. Strategic realignment and operational improvements are essential to achieve a turnaround and create long-term value.

Income Statement

Iterum Therapeutics demonstrates significant financial challenges, evidenced by consistent net losses and negative EBIT over the past years. The absence of revenue and gross profit undermines the potential for profitability. The company faces difficulty in generating income, with no visible growth trajectory in revenue, indicating a need for strategic changes to reverse the negative trend.

Balance Sheet

The balance sheet reveals a precarious financial position with negative stockholders' equity and a high level of liabilities relative to assets. Although the company has managed to reduce net debt, the negative equity indicates financial instability and potential risk for stakeholders. This situation demands a comprehensive approach to improve financial health and sustain operations.

Cash Flow

Iterum Therapeutics exhibits negative operating and free cash flows, highlighting the challenge of maintaining liquidity without external financing. The reliance on financing activities for cash inflows suggests an unsustainable cash flow model. Improving cash generation from operations is crucial to stabilize cash flow and reduce dependency on external capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	390.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-668.00K	-254.00K	-1.75M	-1.80M	-2.10M	-161.00K
EBITDA	-23.07M	-21.73M	-34.58M	-39.97M	-83.20M	-36.01M
Net Income	-26.96M	-24.77M	-38.37M	-44.43M	-91.56M	-52.01M
Balance Sheet
Total Assets	32.50M	44.59M	26.26M	66.83M	91.51M	32.79M
Cash, Cash Equivalents and Short-Term Investments	11.00M	24.13M	23.93M	60.80M	81.34M	14.57M
Total Debt	33.73M	45.53M	18.96M	30.10M	30.43M	48.08M
Total Liabilities	39.88M	48.68M	32.66M	38.83M	41.27M	83.35M
Stockholders Equity	-7.38M	-4.08M	-6.40M	28.00M	50.23M	-50.56M
Cash Flow
Free Cash Flow	-19.93M	-26.77M	-39.34M	-18.54M	-15.90M	-54.54M
Operating Cash Flow	-19.91M	-26.77M	-39.33M	-18.47M	-15.84M	-54.53M
Investing Cash Flow	1.09M	18.21M	23.34M	13.96M	-54.59M	-11.00K
Financing Cash Flow	16.27M	26.69M	1.03M	-1.82M	83.13M	64.47M

Iterum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITRM, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.43, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.64 is Neutral, neither overbought nor oversold. The STOCH value of 47.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITRM.

Iterum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMP	58 Neutral	$307.14M	-2.41	-172.70%	―	―	5.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XLO	49 Neutral	$33.90M	-0.98	-908.28%	―	588.40%	61.76%
RADX	47 Neutral	$59.17M	-1.50	-98.81%	―	―	―
CLNN	45 Neutral	$60.30M	-1.51	―	―	-49.17%	23.37%
ITRM	43 Neutral	$17.22M	-0.44	―	―	―	62.61%
CVM	42 Neutral	$44.31M	-0.68	-176.32%	―	―	48.68%

Iterum Therapeutics Corporate Events

Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge

On December 11, 2025, Iterum Therapeutics received a notification from Nasdaq indicating that it no longer meets the listing requirements due to its market value of listed securities falling below $35 million for 30 consecutive business days. The company has until June 9, 2026, to regain compliance, or it risks delisting. Additionally, Iterum was previously notified on August 25, 2025, about non-compliance with the minimum bid price rule, with a deadline of February 23, 2026, to address this issue. Failure to meet these requirements could lead to delisting, although the company may appeal any delisting decisions.

The most recent analyst rating on (ITRM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.

Iterum Therapeutics Announces $20M Share Offering

On October 16, 2025, Iterum Therapeutics announced a prospectus supplement for the offer and sale of its ordinary shares, aiming to raise up to $20 million under its at-the-market offering agreement. The company has previously raised approximately $36.2 million through similar offerings. In August 2025, Iterum launched ORLYNVAH™ in the U.S. market, expecting modest sales in the early stages of its commercialization efforts.

The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.